Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)
Shots:
- Bio-Thera and STADA have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab)
- Under the collaboration, Bio-Thera is entitled to receive a $10M upfront and an additional $147.5M development and commercial milestones upon certain conditions fulfilment
- Furthermore, Bio-Thera will handle the development, manufacturing and supply activities of BAT2506, while STADA gains an exclusive right to commercialize it across the EU, UK, Switzerland and other selected regions
Ref: Bio-Thera | Image: Bio-Thera
Related News:- Bio-Thera Reports the Initiation of P-III Clinical Trial for BAT2506 (biosimilar- golimumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
